General information about company
Scrip code*		523144
NSE Symbol*		NOTLISTED
MSEI Symbol*		NOTLISTED
ISIN*		INE442D01010
Name of company		MEDI-CAPS LIMITED
Type of company		Main Board
Class of security		Equity
Date of start of financial year		01-04-2025
Date of end of financial year		31-03-2026
Date of board meeting when results were approved		05-08-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange		28-07-2025
Description of presentation currency		INR
Level of rounding		Lakhs
Reporting Type		Quarterly
Reporting Quarter		First quarter
Nature of report standalone or consolidated		Consolidated
Whether results are audited or unaudited for the quarter ended		Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting		Multi segment
Description of single segment
Start date and time of board meeting		05-08-2025 15:00
End date and time of board meeting		05-08-2025 15:40
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification		Not applicable

Financial Results – Ind-AS
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2025	01-04-2025
Date of end of reporting period		30-06-2025	30-06-2025
Whether results are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Consolidated	Consolidated
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1	Income
	Revenue from operations	268.76	268.76
	Other income	33.49	33.49
	Total income	302.25	302.25
2	Expenses
(a)	Cost of materials consumed	169.19	169.19
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-10.35	-10.35
(d)	Employee benefit expense	186.06	186.06
(e)	Finance costs	1.3	1.3
(f)	Depreciation, depletion and amortisation expense	43.68	43.68
(g)	Other Expenses
1	Power Cost	53.47	53.47
2	Freight Expenses	39.7	39.7
3	Other Expenses	168.39	168.39
	Total other expenses	261.56	261.56
	Total expenses	651.44	651.44
3	Total profit before exceptional items and tax	-349.19	-349.19
4	Exceptional items	0	0
5	Total profit before tax	-349.19	-349.19
6	Tax expense
7	Current tax	0	0
8	Deferred tax	0	0
9	Total tax expenses	0	0
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	-349.19	-349.19
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	Net profit (loss) from discontinued operation after tax	0	0
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	Total profit (loss) for period	-349.19	-349.19
17	Other comprehensive income net of taxes	152.44	152.44
18	Total Comprehensive Income for the period	-196.75	-196.75
19	Total profit or loss, attributable to
	Profit or loss, attributable to owners of parent	-349.19	-349.19
	Total profit or loss, attributable to non-controlling interests	0	0
20	Total Comprehensive income for the period attributable to
	Comprehensive income for the period attributable to owners of parent	-196.75	-196.75
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	0	0
21	Details of equity share capital
	Paid-up equity share capital	1247	1247
	Face value of equity share capital	10	10
22	Reserves excluding revaluation reserve
23	Earnings per share
i	Earnings per equity share for continuing operations
	Basic earnings (loss) per share from continuing operations	-2.8	-2.8
	Diluted earnings (loss) per share from continuing operations	-2.8	-2.8
ii	Earnings per equity share for discontinued operations
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
iii	Earnings per equity share (for continuing and discontinued operations)
	Basic earnings (loss) per share from continuing and discontinued operations	-2.8	-2.8
	Diluted earnings (loss) per share from continuing and discontinued operations	-2.8	-2.8
24	Debt equity ratio			Textual Information( 1)
25	Debt service coverage ratio			Textual Information( 2)
26	Interest service coverage ratio			Textual Information( 3)
27	Disclosure of notes on financial results	Textual Information(4)

Text Block

Textual Information(4)

NOTES:

1. The above standalone and consolidated unaudited financial results for the Quarter ended June 30, 2025 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on August 05, 2025. The above results have been reviewed by Statutory Auditors of the Company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Company's Management has exercised the necessary due diligence to ensure that the financial results provide a true and fair view of its affairs.

2. This above standalone and consolidated unaudited financial results has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.

3. The above consolidated results included the results of the wholly owned subsidiary company i.e. Medgel Private Limited.

4. The Company has two reportable segments for the Consolidated Financial Statements which consists of the Pharma division and Real Estate division in accordance with Ind AS-108 Operating Segment and the same is enclosed with this result.

5. The Company has not generated any revenue from operation during this quarter

6. The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or re-casted wherever found necessary.

7. The aforesaid unaudited financial Results will be uploaded on the Company's website www.medicaps.com and will also be available on the websites of the Stock exchange i.e. www.bseindia.com for the benefit of shareholders and investors. Further, publication containing a Quick Response code and the details of the webpage where complete financial results of the Company are available, will be published in English and Hindi Newspapers with in prescribed time limit.

8. The figures of the quarter ended March 31, 2025 are the balancing figure between the audited figures in respect of the full financial year and the years to date figures up to the up to the first quarter which were subject to limited review.

DATE: 05.08.2025 For and on behalf of the Board of Directors of
PLACE: INDORE MEDI-CAPS LIMITED

ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2025	01-04-2025
Date of end of reporting period		30-06-2025	30-06-2025
Whether results are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Consolidated	Consolidated
1	Segment Revenue (Income)
	(net sale/income from each segment should be disclosed)
1	Pharma Devision	268.76	268.76
2	Real Estate Devision	0	0
3	Other	0	0
	Total Segment Revenue	268.76	268.76
	Less: Inter segment revenue
	Revenue from operations	268.76	268.76
2	Segment Result
	Profit (+) / Loss (-) before tax and interest from each segment
1	Pharma Devision	-308.14	-308.14
2	Real Estate Devision	-39.75	-39.75
3	Other	0	0
	Total Profit before tax	-347.89	-347.89
	i. Finance cost	1.3	1.3
	ii. Other Unallocable Expenditure net off Unallocable income	0	0
	Profit before tax	-349.19	-349.19
3	(Segment Asset - Segment Liabilities)
	Segment Asset
1	Pharma Devision	5491.74	5491.74
2	Real Estate Devision	6810.76	6810.76
3	Other	0	0
	Total Segment Asset	12302.5	12302.5
	Un-allocable Assets	0	0
	Net Segment Asset	12302.5	12302.5
4	Segment Liabilities
	Segment Liabilities
1	Pharma Devision	309.72	309.72
2	Real Estate Devision	61.86	61.86
3	Other	0	0
	Total Segment Liabilities	371.58	371.58
	Un-allocable Liabilities	0	0
	Net Segment Liabilities	371.58	371.58
	Disclosure of notes on segments

Other Comprehensive Income
Date of start of reporting period		01-04-2025	01-04-2025
Date of end of reporting period		30-06-2025	30-06-2025
Whether results are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Consolidated	Consolidated
	Other comprehensive income [Abstract]
1	Amount of items that will not be reclassified to profit and loss
1	Items that will not be reclassified to statement of profit & loss	152.44	152.44
	Total Amount of items that will not be reclassified to profit and loss	152.44	152.44
2	Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00
3	Amount of items that will be reclassified to profit and loss
	Total Amount of items that will be reclassified to profit and loss
4	Income tax relating to items that will be reclassified to profit or loss
5	Total Other comprehensive income	152.44	152.44

General information about company

Financial Results – Ind-AS

Text Block

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results

Other Comprehensive Income